1. KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats;Andreassen;Mol. Metabol.,2021
2. Anti-obesity medications and investigational agents: an obesity medicine association (OMA) clinical practice statement (CPS) 2022;Bays;Obes. Pillars,2022
3. Cagrilintide plus semaglutide for obesity management;Becerril;Lancet,2021
4. Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates;Bello;Am. J. Physiol. Integr. Comp. Physiol.,2010
5. Semaglutide for the treatment of overweight and obesity: a review;Bergmann;Diabetes Obes. Metabol.,2022